Trial Profile
A trial assessing efficacy of Imatinib mesylate in patients with relapsed/refractory peripheral T cell lymphoma (T-cell non-Hodgkin lymphoma).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 May 2016
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma
- Focus Therapeutic Use
- 02 May 2016 New trial record